Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Serlopitant - VYNE Therapeutics

Next Previous
Drug Profile

Serlopitant - VYNE Therapeutics

Alternative Names: JTS 661; MK-0594; VPD-737

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Japan Tobacco; Menlo Therapeutics; Merck & Co; Torii Pharmaceutical
  • Class Antipruritics; Antitussives; Cyclopentanes; Isoindoles; Skin disorder therapies; Small molecules; Urologics
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alcoholism; Cough; Overactive bladder; Pruritus

Most Recent Events

  • 24 Jun 2022 Stanford University, Epidermolysis Bullosa Research Partnership and Menlo Therapeutics completes a phase II trial in Pruritus (In adolescents, In adults, In the elderly) in USA (PO, Tablet) (NCT03836001)
  • 08 Sep 2020 Menlo Therapeutics is now called VYNE Therapeutics
  • 17 Jun 2020 Menlo Therapeutics terminates a phase III trial in Pruritus (associated with prurigo nodularis, atopic dermatitis, or psoriasis) in USA, Austria, Germany, Poland (PO) (NCT03540160)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top